ReviewAnnual review of pathology2022
Innate Immunity and Cancer Pathophysiology.
Review in Annual review of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 136 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
136 citing papers in PubMed, 3 syntheses or guidelines pooled it, 189 citations in OpenAlex.
- Role of nutritional (PNI, CONUT) and inflammatory indices (SII) in predicting lymph node metastasis and prognosis of thyroid cancer: a systematic review and meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Pooled it
- Long-term prognostic value of postoperative C-reactive protein in gastric cancer patients: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- A Systematic Review of Immune Cell Roles in Breast Cancer Immunotherapy.Cancer reports (Hoboken, N.J.) · 2025Pooled it
- A nomogram for distinguishing benign and malignant parotid gland tumors using clinical data and preoperative blood markers: development and validation.Journal of cancer research and clinical oncology · 2023Trial
- Overcoming melanoma drug resistance: Mechanisms and clinical progress of oncolytic viruses combined with immune checkpoint inhibitors (Review).Oncology reports · 2026Review
- Tumor microenvironment-rearranging Nanoassemblies overcome angiogenesis-immunotherapy resistance to potentiate osteosarcoma treatment.Materials today. Bio · 2026Article
- B Cells and Tumor Immunometabolism: Emerging Insights into Immune Regulation and Therapeutic Resistance.Antibodies (Basel, Switzerland) · 2026Review
- Biomimetic Scaffold-Based 3D Models for Decoding Cancer Biology and Advancing Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Early Identification and Prognostic Stratification of Cancer Cachexia Using Explainable Machine Learning: A Multicentre Cohort Study.Journal of cachexia, sarcopenia and muscle · 2026Observational
- Retrospective cohort study on prognostic factors of malignant pleural effusion secondary to pleural mesothelioma.Journal of thoracic disease · 2026Article
- Beyond TNM staging: validation of a CT-derived nutritional-inflammatory composite model (RFMmSIS) for prognostication in resectable gastric cancer.BMC cancer · 2026Article
- Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics.Signal transduction and targeted therapy · 2026Review
- PANoptosis in life and death across cell types: From innate immunity to therapeutic implications.Cell chemical biology · 2026Review
- Anti-angiogenic therapy combined with immune checkpoint blockade mediates CCR7 + CD8 + T-cell entry into HCC through high endothelial venules.Hepatology (Baltimore, Md.) · 2026Article
- APLP2 as a molecular link between immune regulation and bone metabolism in hepatocellular carcinoma: evidence from scRNA-seq and functional validation.Cancer cell international · 2026Article
- Nanotechnology-enabled modulation of reactive oxygen species in cancer and chronic inflammation: a systematic review of therapeutic advances and translational challenges.Discover nano · 2026Review
- Macrophage Extracellular Traps in Immunity and Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The predictive value of contrast-enhanced CT characteristics combined with composite inflammatory markers for lymph node metastasis in T1 colorectal cancer.International journal of colorectal disease · 2026Article
- Article
- LL-37: Biological Mechanisms and Emerging Therapeutic Applications in Intestinal Disease.Immunity, inflammation and disease · 2026Review
76 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Chronic inflammation increases the risk of several cancers, including gastric, colon, and hepatic cancers. Conversely, tumors, similar to tissue injury, trigger an inflammatory response coordinated by the innate immune system. Cellular and molecular mediators of inflammation modulate tumor growth directly and by influencing the adaptive immune response. Depending on the balance of immune cell types and signals within the tumor microenvironment, inflammation can support or restrain the tumor. Adding to the complexity, research from the past two decades has revealed that innate immune cells are highly heterogeneous and plastic, with variable phenotypes depending on tumor type, stage, and treatment. The field is now on the cusp of being able to harness this wealth of data to (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.